Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Allopurinol

Drug and asset intelligence for Allopurinol with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
1
Stage
Development stage unavailable

Sponsor company

Gout →

Recent signals(2)

RegulatoryJuly 25, 2026

FDA Accepts Supplement for Dr Reddy's Allopurinol ANDA071587

The FDA has accepted a supplemental application for Dr Reddy's allopurinol under ANDA071587.

ClinicalJuly 13, 2026

Phase II Study of D-0120 and Allopurinol in Gout by InventisBio

InventisBio is conducting Phase II trial to evaluate the efficacy and safety of D-0120 in combination with Allopurinol for treating gout.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Allopurinol

July 13, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Gout →
Rheumatology →
Rheumatology · Gout →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.